Vnitr Lek 2020, 66(5):e20-e25 | DOI: 10.36290/vnl.2020.093

Pulmonary‑renal syndrome

Zdenka Hrušková, Vladimír Tesař
Klinika nefrologie 1. LF UK a VFN v Praze

Pulmonary syndrome is defined by occurrence of lung involvement (alveolar haemorrhage) in association with renal failure (with a typical crescentic necrotizing rapidly progressive glomerulonephritis). It is caused by an autoimmune disease, most frequently ANCA-associated vasculitides and anti-GBM (glomerular basement membrane) disease. Early establishment of the right diagnosis and immediate treatment are crucial for favourable prognosis of the patients. First choice therapy includes high-dose corticosteroids and cyclophosphamide, usually with plasma exchange added. Newer therapeutic possibilities include especially rituximab even though there is limited experience with its use in the settings of the most severe cases of pulmonary syndrome.

Keywords: ANCA, anti‑glomerular basement membrane (anti‑GBM) antibodies, diffuse alveolar haemorrhage, rapidly progressive glomerulonephritis, rituximab, vasculitis.

Published: August 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hrušková Z, Tesař V. Pulmonary‑renal syndrome. Vnitr Lek. 2020;66(5):e20-25. doi: 10.36290/vnl.2020.093.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. West SC, Arulkumaran N, Ind PW, et al. Pulmonary‑renal syndrome: a life threatening but treatable condition. Postgrad Med J 2013; 89: 274-283. Go to original source... Go to PubMed...
    2. McCabe C, Jones Q, Nikolopoulou A, et al. Pulmonary‑renal syndromes: an update for respiratory physicians. Respir Med 2011; 105: 1413-1421. Go to original source... Go to PubMed...
    3. Tesař V, Honsová E, Ryšavá R, et al. Glomerulopatie. In: Tesař V, Viklický O (eds.) Klinická nefrologie. Praha: Grada 2015; 91-164.
    4. Hrušková Z, Tesař V. Rychle progredující glomerulonefritidy - novinky v léčbě. Postgraduální medicína 2015; 5: 27-32.
    5. Moroni G, Ponticelli C. Rapidly progressive crescentic glomerulonephritis: Early treatment is a must. Autoimmun Rev 2014; 13: 723-729. Go to original source... Go to PubMed...
    6. Greenhall GH, Salama AD. What is new in the management of rapidly progressive glomerulonephritis? Clin Kidney J 2015; 8: 143-150. Go to original source... Go to PubMed...
    7. Xiao H, Hu P, Falk RJ, et al. Overview of the Pathogenesis of ANCA‑Associated Vasculitis. Kidney Dis (Basel) 2016; 1: 205-215. Go to original source... Go to PubMed...
    8. Hruskova Z, Casian AL, Konopasek P, et al. Long‑term outcome of severe alveolar haemorrhage in ANCA‑associated vasculitis: a retrospective cohort study. Scand J Rheumatol 2013; 42: 211-214. Go to original source... Go to PubMed...
    9. Yates M, Watts RA, Bajema IM, et al. EULAR/ERA‑EDTA recommendations for the management of ANCA‑associated vasculitis. Ann Rheum Dis 2016; 75: 1583-1594. Go to original source... Go to PubMed...
    10. Casian A, Jayne D. Management of alveolar hemorrhage in lung vasculitides. Semin Respir Crit Care Med 2011; 32: 335-345. Go to original source... Go to PubMed...
    11. Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised international Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis & Rheum 2013; 65: 1-11. Go to original source... Go to PubMed...
    12. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2012; 2: 139-274.
    13. Ntatsaki E, Carruthers D, Chakravarty K, et al. BSR and BHPR guideline for the management of adults with ANCA‑associated vasculitis. Rheumatology (Oxford) 2014; 53: 2306-2309. Go to original source... Go to PubMed...
    14. Tesar V, Hruskova Z. Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies‑associated vasculitis - still of value for our patients? Expert Opin Pharmacother 2015; 16: 1683-1702. Go to original source... Go to PubMed...
    15. De Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody‑associated vasculitis: a randomized trial. Ann Intern Med 2009; 150: 670-680. Go to original source... Go to PubMed...
    16. Pepper RJ, Chanouzas D, Tarzi R, et al. Intravenous cyclophosphamide and plasmapheresis in dialysis‑dependent ANCA‑associated vasculitis. Clin J Am Soc Nephrol 2013; 8: 219-224. Go to original source... Go to PubMed...
    17. Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA‑associated vasculitis: long‑term follow‑up. Ann Rheum Dis 2012; 71: 955-960. Go to original source... Go to PubMed...
    18. Jayne D, Rasmussen N, Andrassy K, et al. European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44. Go to original source... Go to PubMed...
    19. Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody‑associated vasculitis: a randomized controlled trial. JAMA 2010; 304: 2381-2388. Go to original source... Go to PubMed...
    20. Walsh M, Catapano F, Szpirt W, et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta‑analysis. Am J Kidney Dis 2011; 57: 566-574. Go to original source... Go to PubMed...
    21. Walsh M, Casian A, Flossmann O, et al. Long‑term follow‑up of patients with severe ANCA‑associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 2013; 84: 397-402. Go to original source... Go to PubMed...
    22. Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoid dosing in the treatment of anti‑neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 2013; 14: 73. Go to original source... Go to PubMed...
    23. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA‑associated vasculitis. N Engl J Med 2010; 363: 221-232. Go to original source... Go to PubMed...
    24. Jones RB, Tervaert JW, Hauser T et al. Rituximab versus cyclophosphamide in ANCA‑associated renal vasculitis. N Engl J Med 2010; 363: 211-220. Go to original source... Go to PubMed...
    25. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA‑associated vasculitis. N Engl J Med 2014; 371: 1771-1780. Go to original source... Go to PubMed...
    26. Terrier B, Pagnoux C, Perrodeau É et al. Long‑term efficacy of remission‑maintenance regimens for ANCA‑associated vasculitides. Ann Rheum Dis 2018; 77: 1150-1156. Go to original source...
    27. Geetha D, Hruskova Z, Segelmark M, et al. Rituximab for treatment of severe renal disease in ANCA associated vasculitis. J Nephrol 2015; 41: 296-301. Go to original source... Go to PubMed...
    28. Pepper RJ, McAdoo SP, Moran SM, et al. A novel glucocorticoid‑free maintenance regimen for anti‑neutrophil cytoplasm antibody‑associated vasculitis. Rheumatology (Oxford) 2019; 58: 260-268. Go to original source... Go to PubMed...
    29. McAdoo SP, Medjeral‑Thomas N, Gopaluni S, et al. Long‑term follow‑up of a combined rituximab and cyclophosphamide regimen in renal anti‑neutrophil cytoplasm antibody‑associated vasculitis. Nephrol Dial Transplant 2019; 34: 63-73. Go to original source... Go to PubMed...
    30. Hellmark T, Segelmark M. Diagnosis and classification of Goodpasture's disease (anti‑GBM). J Autoimmun 2014; 48-49: 108-112. Go to original source... Go to PubMed...
    31. McAdoo SP, Tanna A, Hrušková Z, et al. Patients double‑seropositive for ANCA and anti‑GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single‑seropositive patients. Kidney Int 2017; 92: 693-702. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.